StockData

Fate Therapeutics vs Lineage Cell Therapeutics

FATE and LCTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How FATE and LCTX compare

Lineage Cell Therapeutics is the larger company, worth 1.5 times as much as Fate Therapeutics ($201M against $137M).

Lineage Cell Therapeutics grew revenue faster over the last twelve months (19.9% versus −23.4% for Fate Therapeutics).

Lineage Cell Therapeutics keeps more of each dollar of sales as profit, with a net margin of −247% compared with −1941% at Fate Therapeutics.

Lineage Cell Therapeutics scores higher on the StockData Score (8 against 7 for Fate Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricFATELCTX
Size and price
Market cap$137M$201M
Share price$1.14$0.795
Change, 1 year14.9%−55.8%
Change, 5 years−97.8%−60.0%
Beta (5Y)3.841.21
Employees16177
StockData Score
Total score78 (better)
Valuation score2 (better)0
Growth score01 (better)
Performance score02 (better)
Health score55
Dividend score00
Valuation
P/S21.0×15.4× (better)
P/B0.9× (better)3.3×
FCF yield−77.3%−12.1% (better)
Fair value$1.33$0.657
Margin of safety14.3% (better)−21.0%
Growth
Revenue growth (TTM)−23.4%19.9% (better)
Revenue growth, 5Y average−26.7%51.5% (better)
Profitability
Operating margin−2058%−205% (better)
Net margin−1941%−247% (better)
FCF margin−1627%−186% (better)
Return on equity−60.7%−59.0% (better)
Return on invested capital−553%−262% (better)
Financial health
Debt / equity0.000.00
Current ratio4.856.61 (better)
Altman Z-score−8.91−3.80 (better)
Piotroski F-score34 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions59.9%46.1%
Held by insiders25.7%74.4%
Insider net buying, 12 months−$336K$24.4K (better)
Short interest, % of float11.2%37.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.